Navigation Links
ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease
Date:2/26/2009

PARIS, February 26 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) is pleased to announce that clinical testing of EHT 0202, its lead compound in Alzheimer's disease, is progressing well. Patient enrolment for the Phase IIa trial assessing EHT 0202 in patients with Alzheimer's disease is completed.

"The successful completion of patient enrolment for the Phase IIa represents an important milestone in the development of EHT 0202, and provides a clear timeline for the release of results," stated Dr. Loic Maurel, President of the Management Board of ExonHit Therapeutics. "Our strategy is to bring EHT 0202 up to the end of the ongoing study and then to look for a partner to move EHT 0202 through further clinical development. We have already met with several pharmaceutical companies that are looking forward to the Phase IIa results."

The trial is conducted under the supervision of Professor Bruno Vellas, Head of Alzheimer's Disease Clinical Research Center and Gerontopole, Toulouse University Hospital, France.

"EHT 0202 has an original mechanism of action: it stimulates the alpha-secretase pathway. If the neuroprotective and symptomatic effects of EHT 0202 demonstrated in animal models are confirmed in humans, it could change the treatment paradigm for Alzheimer's disease," stated Professor Vellas. "Current available drugs are symptomatic only and their clinical efficacy is limited over time, after which the evolution of the degenerative process starts progressing again. EHT 0202 is an interesting approach to potentially slow the evolution of the disease."

The Phase IIa trial is a multicenter, randomized, double-blind, placebo-controlled study primarily investigating the safety and tolerability of EHT 0202 in approximately 150 patients with Alzheimer's disease. The effect of two different doses of EHT 0202 as adjunctive therapy to an acetylcholinesterase inhibitor
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
2. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
3. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
4. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
7. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
8. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
11. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Inc. (NASDAQ:INSM), a ,biopharmaceutical company focused on the development ... diseases with unmet,medical needs, today announced that it ... Growth,Opportunities Conference in New York City. ... Oriental Hotel in New,York City, will run from ...
... 9, 2007 - Neose Technologies,Inc. (NasdaqGM:NTEC) announced today ... Emerging Growth Opportunities Conference,held at the Mandarin Oriental ... The Company's presentation is scheduled for 2:00 p.m.,(EDT) ... be webcast,live and available for replay via the ...
Cached Medicine Technology:Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference 2
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective ... immunocompromised patients. This is the result of a study ... Center for Women,s Gastrointestinal Medicine at The Women,s Medicine ... online in advance of print in the American ... or C. diff , has increased to epidemic ...
(Date:7/9/2014)... are personal and subjective, the human brain turns ... emotions across different senses, situations and even people, ... Adam Anderson. , "We discovered that fine-grained patterns ... area of the brain associated with emotional processing, ... individual,s subjective feeling," says Anderson, associate professor of ...
(Date:7/9/2014)... 8, 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at ... 12 July 17 in Copenhagen, Denmark. Data from ... prompt transition from cognitive normality to mild cognitive impairment ... Einstein Aging Study , established in 1980 to examine ...
(Date:7/9/2014)... smell of flatulence and have a reputation for being highly ... sulfide is now being being found to offer potential health ... heart attacks and dementia. A new compound (AP39), designed and ... to future therapies, by targeting delivery of very small amounts ... cells. , Scientists in Exeter have already found that ...
(Date:7/9/2014)... conducted by researchers at Tufts University School of Dental ... and developmental disabilities, the likelihood of having cavities decreased ... The findings, published in the July/August issue of ... designed to address the oral health of individuals in ... records of 107 patients at one of the eight ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... , , , WASHINGTON, ... Produce Safety Project: , , We commend the FDA ... The proposed guidance documents put out for comment today address three ... these documents quickly. We also look forward to the agency,s next ...
... ... in Webinar Series on "How Generation and Gender Impact Physician Engagement" , ... Charlotte, N.C. (Vocus) July 31, 2009 -- ... in Physician Engagement." The free hour-long ,webinar will be broadcast on Wednesday, August ...
... SHENZHEN, China, July 31 /PRNewswire-FirstCall/ ... announced today that its,registration dossier for MEVAC-DTaP (Diphtheria, Tetanus ... consideration,of the experts in Thai FDA. The sample analysis ... , Mr. Terry Yuan CEO ...
... , COLUMBIA, S.C., July 31 Amid rising ... benefits of including international medical travel coverage in their employee ... possible risks associated with offering such options. , , ... Global Healthcare Inc. today announced an agreement with an insurer ...
... skills, researchers say , FRIDAY, July 31 (HealthDay News) ... should learn cardiopulmonary resuscitation (CPR), Austrian researchers say. , In ... life-support training, 86 percent of the children performed CPR correctly ... to the report published online in the journal Critical ...
... , , , ... Language Line Services , the leading provider of ... evening, July 23rd at a Recognition and Awards Banquet at Bellevue University, ... Wray, President of the Nebraska Association for Translators & Interpreters (NATI), said, ...
Cached Medicine News:Health News:Webinar on "Physician Engagement - Diagnosing Generational Differences" Presented by Morehead Associates 2Health News:Webinar on "Physician Engagement - Diagnosing Generational Differences" Presented by Morehead Associates 3Health News:Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier 2Health News:Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier 3Health News:New Policies Protect Employers, Workers Who Choose Global Health Care 2Health News:Even 9-Year-Olds Can Learn CPR 2Health News:Language Line Services Honored by Nebraska Association for Translators & Interpreters (NATI) 2Health News:Language Line Services Honored by Nebraska Association for Translators & Interpreters (NATI) 3
When You Need Optimal Patient Comfort with Minimal Weight at a Nonunion Site...Demand The OrthoPak Noninvasive Bone Growth Stimulator., ,Most Appropriate for the Proximal Femur, Metatarsal/Tarsal...
... Providing the surgical versatility you demand when ... new EBI OsteoGen-D offers 40 microamperes of ... each with 20 microamperes. Available in both ... superior flexibility with any of your bone ...
... cataract surgery following refractive surgery grows larger ... for surgeons, as calculating IOL power for ... power following RK, ALK, PRK and LASIK ... or topography. For example, keratometry and simulated ...
... to offer one of the ... at only 188 grams! The ... superior flow rate with effortless ... The complementing electrodes provide powerful ...
Medicine Products: